NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics' shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafae ...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Niemann-Pick disease - Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Niemann-Pick disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of admi ...

分组1 - Cyclo Therapeutics reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, and compared to a loss of $0.29 per share a year ago, indicating a surprise of -52.94% [1] - The company posted revenues of $0.23 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 24.52%, and down from $0.5 million in the same quarter last year [2] - Cyclo Therapeutics shares have declined approximately 54.7% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] 分组2 - The earnings outlook for Cyclo Therapeutics is uncertain, with current consensus EPS estimates at -$0.19 on $0.21 million in revenues for the upcoming quarter and -$0.72 on $0.89 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] - The estimate revisions trend for Cyclo Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2024 or ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |------------------------- ...

MILWAUKEE, Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Cyclo Therapeutics stockholders will receive only a certain number of shares of Class B common stock of Rafael Ho ...

NEW YORK, Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into t ...

Group 1 - Cyclo Therapeutics, Inc. reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of -50% [1] - The company posted revenues of $0.12 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 69.25%, with no year-over-year revenue growth [2] - Cyclo Therapeutics shares have declined approximately 26.4% since the beginning of the year, contrasting with the S&P 500's gain of 13.9% [3] Group 2 - The earnings outlook for Cyclo Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.15 on revenues of $0.4 million, and -$0.62 on revenues of $1.5 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |----------------------------- ...

NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. "During fiscal 2024, we have continued to develop our existing portfolio while actively evaluating opportunities for strategic investment," said Bill Conkling, CEO of Rafael Holdings. Bill added, "We are particularly pleased that Cyclo Therapeutics (Nasdaq:CYTH) announced the completion of enrollment in it ...

FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 or ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ...